An interventional study of Lycium Barbarum Polysaccharide in Dry Eye Syndromes, sponsored by The Hong Kong Polytechnic University. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment
The goal of this pilot clinical study is to learn if Lycium barbarum polysaccharide (LBP) supplementation helps manage dry eye disease in adults. It will also learn about the safety of LBP supplementation.
The main questions it aims to answer are:
Researchers will evaluate changes in dry eye symptoms and eye examination results before and after LBP supplementation.
Participants will:
Dry eye disease is associated with disruption of tear film homeostasis, ocular surface inflammation, and ocular discomfort. Current management often includes lubricating eye drops and other supportive approaches, but additional interventions that may support ocular surface health remain of interest.
Lycium barbarum polysaccharide is a bioactive component derived from goji berry. Previous laboratory and animal studies suggest that it may have antioxidant, anti-inflammatory, and neuroprotective effects relevant to ocular surface disease. However, clinical data on its use in people with dry eye disease are limited.
This pilot study will generate preliminary clinical information on oral Lycium barbarum polysaccharide supplementation in adults with dry eye disease. The study will use standardized optometric assessments in a clinical research setting to characterize changes in dry eye-related symptoms and ocular surface findings over the study period.
Information from this pilot study may help determine whether further investigation of Lycium barbarum polysaccharide supplementation in dry eye disease is warranted in a larger controlled trial.
1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.
This study's planned enrollment of 30 is below the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →The Hong Kong Polytechnic University is the lead sponsor of 679 studies on the registry; 257 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral Lycium barbarum polysaccharide supplementation for 12 weeks.
Dietary Supplement: Lycium Barbarum Polysaccharide
Participants will take Lycium barbarum polysaccharide tablets orally for 12 weeks. The dosing regimen is two tablets twice daily, for a total of four tablets per day. Each tablet contains Lycium barbarum glycoconjugates, blueberry powder, and grape seed extract.
Also known as: LBP, Goji glycoconjugates, Viso I
Change in 12-Item Ocular Surface Disease Index Score
The 12-item Ocular Surface Disease Index (OSDI-12) assesses dry eye symptoms. Scores range from 0 to 100, with higher scores indicating worse symptoms. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Change in First Non-Invasive Tear Break-Up Time
First non-invasive tear break-up time will be measured in seconds using the Oculus Keratograph 5M. Longer times indicate greater tear film stability. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Change in Tear Film Lipid Layer Thickness
Tear film lipid layer thickness will be measured in nanometers using the IDRA Ocular Surface Analyzer. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Change in Tear Meniscus Height
Lower tear meniscus height will be measured in millimeters using the Oculus Keratograph 5M. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Change in Corneal Sensitivity Threshold
Corneal sensitivity threshold will be measured in millibars using the Brill non-contact corneal esthesiometer. Lower thresholds indicate greater corneal sensitivity. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Change in Schirmer Test Wetting Length
Tear production will be assessed using the Schirmer test, with strip wetting length recorded in millimeters after 5 minutes. Greater wetting length indicates greater tear production. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Change in Visual Acuity
Monocular visual acuity will be measured using a standard visual acuity chart and recorded as a Snellen fraction. Follow-up testing will use the baseline objective refraction, where available; otherwise, habitual visual acuity will be used. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Change in National Eye Institute Corneal Fluorescein Staining Score
Corneal fluorescein staining will be graded using the National Eye Institute scale, with total scores ranging from 0 to 15 per eye. Higher scores indicate more severe staining. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Change in National Eye Institute Conjunctival Lissamine Green Staining Score
Conjunctival lissamine green staining will be graded using the National Eye Institute scale, with total scores ranging from 0 to 18 per eye. Higher scores indicate more severe staining. Change from baseline to Week 12 will be assessed.
Time frame: Baseline and Week 12
Plan to share: No — There is currently no plan to share individual participant data. Researchers may contact the corresponding author with data-related inquiries. Any future sharing would require review by the study team and compliance with applicable ethics and institutional requirements.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lycium barbarum polysaccharide
The Hong Kong Polytechnic University →